Severe pseudomembranous colitis after moxifloxacin use: A case series

Annals of Pharmacotherapy

Volumn 43, Issue 1, 2009, Pages 123-128

  Gallagher, Jason C ^a,c   Du, Jennifer K ^b   Rose, Christina ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sutter Infusion and Pharmacy Services   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Clostridium difficile; Fluoroquinolone; Moxifloxacin; Pseudomembranous colitis

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM ACETATE; CEFOXITIN; CLONAZEPAM; FERROUS SULFATE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GUAIFENESIN; LEVOFLOXACIN; LISINOPRIL; LOPERAMIDE; LORATADINE; METOCLOPRAMIDE; METOPROLOL; METRONIDAZOLE; MOXIFLOXACIN; NIFEDIPINE; PANTOPRAZOLE; PAROXETINE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; SALBUTAMOL; SALMETEROL; SEVELAMER; TIOTROPIUM BROMIDE; VANCOMYCIN; ZOLPIDEM; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE; COLON RESECTION; DIARRHEA; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; LOOSE FECES; LUNG INFECTION; MALE; NARANJO PROBABILITY SCALE; PATIENT MONITORING; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RATING SCALE; TREATMENT OUTCOME; CHEMICALLY INDUCED; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FATALITY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FATAL OUTCOME; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLINES; FLUOROQUINOLONES;

EID: 58549085969     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L335     Document Type: Article

References (28)

1. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998;49:375-90.
2. Owens RC. Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26:299-311.
3. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
4. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
5. Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis 2007;45:1266-73.
6. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 2007;35:300-7.
7. Bartlett JG, Perl TM. The new Clostridium difficile - what does it mean (letter)? N Engl J Med 2005;353:2503-5.
8. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
9. Surawicz CM. Antibiotics and Clostridium difficile: cause and cure. J Clin Gastroenterol 2007;41:1-2.
10. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis (letter). N Engl J Med 1994;330:257-62.
11. Golledge CL, Carson CF, O'Neill GL, Bowman RA, Riley TV. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1992;30:141-7.
12. Bates CJ, Wilcox MH, Spencer RC, Harris DM. Ciprofloxacin and Clostridium difficile infection (letter). Lancet 1990;336:1193.
13. Cain DB, O'Connor ME. Pseudomembranous colitis associated with ciprofloxacin (letter). Lancet 1990;336:946.
14. Bauwens JE, McFarland LV, Melcher SA. Recurrent Clostridium difficile disease following ciprofloxacin use (letter). Ann Pharmacother 1997;31:1090.
15. McFarland LV, Bauwens JE, Melcher SA, Surawicz CM, Greenberg RN, Elmer GW. Ciprofloxacin-associated Clostridium difficile disease. Lancet 1995;346:977-8.
16. Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin treatment. Term Med 2002;95:113-5.
17. Carroll DN. Moxifloxacin-induced Clostridium difficile-associated diarrhea. Pharmacotherapy 2003;23:1517-9.
18. Ortiz-de-Saracho J, Pantoja L, Romero MJ, Lopez R. Moxifloxacin-induced Clostridium difficile diarrhea (letter). Ann Pharmacother 2003;37:452-3. DOI 10.1345/aph.1C325
19. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
20. Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 17-20, 2007:K-425a.
21. Gerding DN, Muto CA, Owens J, Robert C. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl):S32-42.
22. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
23. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-5.
24. Biller P, Shank B, Lind L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007;28:198-201.
25. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
26. McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007;45:1141-51.
27. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 2006;50:3216-9.
28. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006;42:73-81.